TuHURA Biosciences, Inc.

Kineta Merger Closed June Kineta Merger closed June 30, 2025, adding TBS-2025 asset; recognized $13.6M Goodwill in preliminary allocation.

June Financing Secured $12.6M June 2025 Private Placement secured $12.6M gross proceeds; financing activities provided $13.4M net cash inflow for nine months.

R&D Investment Increased Substantially Nine-month R&D expenses reached $14.5M, increasing $5.1M to support IFx-2.0 and TBS-2025 clinical development.

Low Cash Reserves Noted Cash reserves stood at $2.7M as of September 30, 2025; substantial doubt on continuing operations without further funding noted.

Operating Losses Widened Significantly Nine-month Net Loss widened to $23.3M from $15.7M year prior; operating loss increased by $11.7M.

FDA Disruptions Risk Delays FDA funding shortages risk hindering review ability, potentially delaying IFx-2.0 approval and commercialization timelines.

Increased G&A Expenses General and administrative expenses rose $6.5M to $9.1M, driven by merger costs and public company compliance expenses.

Future Funding Needs Anticipated Expect substantial future funding required via equity, debt, or partnerships; ATM program filed for up to $50.0M post-period.

Advance Key Pipeline Candidates Advance IFx-2.0 Phase 3 trial and plan TBS-2025 Phase 2 trial investigation in mutated NPM1 AML patients.

Liquidity Sufficient Through 2025 Existing capital, bridge loan, and recent financing expected to fund planned operations into the end of 2025.